Therapeutics and Diagnostics for Cancer & Fibrosis
FAKnostics is a University of Arizona spinoff developing novel therapeutics and diagnostics targeting Focal Adhesion Kinase (FAK) to combat metastatic cancers and fibrosis. Unlike competitors targeting the kinase domain, FAKnostics' inhibitors target the non-kinase domain to overcome drug resistance. Their FAKnosTest companion diagnostic is based on proprietary FAK antibodies validated on thousands of clinical samples.
Tech & App Stack is available on paid plans
Upgrade to Silver or higher to reveal the full technology and app stack for any company.
View pricing
Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.
China's leading mRNA biotech company developing therapeutics for cancer and infectious diseases.
Late-stage biopharma using single-molecule tracking, AI, and engineering to discover and develop ...
